Ruxolitinib（INCB018424）

英文名 ：≥98%(HPLC)

库存 ：50

CAS号 ：941678-49-5

规格 ：10mg/100mg

一种JAK1、JAK2和JAK3抑制剂， IC50分别为0.8nM、2.8nM和10.7nM，具有潜在的抗肿瘤和免疫调节活性。 Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies。